Different approach in high-cardiovascular-risk women, compared to men: A multidisciplinary study-Spain;Diferencias en la atención de las mujeres con alto riesgo cardiovascular respecto a los varones: Estudio multidisciplinario

Medicina Clinica

Volumn 120, Issue 12, 2003, Pages 451-455

  Conthe Gutiérrez, Pedro ^a   Lobos Bejarano, José María ^b   González Juanatey, José Ramón ^c   Gil Núñez, Antonio ^a   Pajuelo Fernández, Francisco Javier ^e   Novials Sardá, Ana ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Medicina de Familia   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d Fundacion Sarda Farriol   (Spain)

^e NONE

Author keywords

Cardiovascular diseases; Drug therapy; Sex factors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOCRINOLOGY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INTERNAL MEDICINE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; NEUROLOGY; PERIPHERAL VASCULAR DISEASE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING HABIT; SPAIN; STROKE;

EID: 0038664224     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13046070     Document Type: Article

References (12)

1. Wood D, De Backer G, Faegerman O, Faegerman O, Graham I, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-503.
2. Kannel WB, Wilson WF. An update on coronary risk factors. Med Clin North Am 1995;79:951-7.
3. 9 WHO-ISH. Guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
4. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413.
5. Garg R, Yusuf S, for the collaborative group on ACE inhibitor trial. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
6. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet theraphy-I. Prevention of death myocardial ifarction nad stroke by prolongued antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615.
8. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Beta-blokers in heart failure: meta-analysis of randomized trials. Circulation 1998;98:1184-91.
9. Krumholz HIM.: Blocker for mild to moderate heart failure. Lancet 1999;353:2-3.
10. Alonso A, Ortigosa J, Antorrena I, Toquero J, Arroyo R, Conthe P. Tratamiento hormonal sustitutivo en la prevención de la cardiopatía isquémica en la mujer: argumentos en contra. Rev Esp Cardiol 2001;54:499-506.
11. Lewis SJ. Cholesterol and coronary heart disease in women. Cardiology Clinics 1998;16:1.
12. Rubies-Prat J, Pedro-Botet J. El riesgo cardiovascular en la mujer posmenopáusica. Med Clin (Barc) 1995;104:695-6.